Related Experiment Video
Updated: Jul 6, 2025
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report
Niki Armstrong1, Susan Apkon2, Kiera N Berggren3
1Parent Project Muscular Dystrophy, Washington, DC, USA.
Insights
Early diagnosis and care for Duchenne muscular dystrophy (DMD) in infants aged 0-3 years are crucial. This meeting highlighted the need for evidence-based guidelines and comprehensive support for families managing DMD.
Area of Science:
- Pediatric Neuromuscular Disorders
- Genetics and Rare Diseases
Background:
- Duchenne muscular dystrophy (DMD) diagnosis and care for infants (0-3 years) present unique challenges.
- Limited evidence-based guidelines exist for early DMD management.
- Female carriers of DMD also require specific attention and care strategies.
Framework:
- The meeting convened experts to discuss advancements in DMD diagnosis and care for young children.
- Key areas included diagnostic delays, ethnic disparities, and newborn screening potential.
- Discussions covered approved therapies (corticosteroids, exon-skipping) and ongoing clinical trials (ataluren, vamorolone, gene therapy).
Implementation:
- Emphasis on timely diagnosis and addressing diagnostic disparities.
- Exploration of early intervention with corticosteroids and safety of exon-skipping drugs.
- Focus on clinical trials for infants and young boys, including novel gene therapies.
Implications:
- Need for developing evidence-based guidelines for early DMD care (0-3 years).
- Importance of comprehensive family support, including information and early intervention services.
- Call for further research, collaboration, and consensus to improve outcomes for children with DMD and their carriers.
Objective:
This report summarizes the key discussions from the "Early Care (0-3 years) in Duchenne Muscular Dystrophy" meeting, which aimed to address the challenges and opportunities in the diagnosis and care of Duchenne muscular dystrophy (DMD) and female carriers within the 0-3-year age group.
Methods:
The meeting brought together experts and healthcare providers who shared insights, discussed advancements in DMD care, and identified research needs. Presentations covered diagnostic challenges, approved therapies, clinical trials, identification of young female carriers, and the importance of clinical care and support for families.
Results:
The meeting highlighted the importance of timely diagnosis and the lack of evidence-based guidelines for the care of children with DMD aged 0-3 years. Diagnostic challenges were discussed, including delays in receiving a DMD diagnosis and disparities based on ethnicity. The potential benefits and process of newborn screening were addressed.Approved therapeutic interventions, such as corticosteroids and exon-skipping drugs, were explored, with studies indicating the potential benefits of early initiation of corticosteroid therapy and the safety of exon-skipping drugs in DMD. Clinical trials involving infants and young boys were discussed, focusing on drugs like ataluren, vamorolone, and gene therapies.The meeting emphasized the importance of clinical care and support for families, including comprehensive information provision, early intervention services, and individualized support. The identification and care of young female carriers were also addressed.
Conclusion:
The meeting provided a platform for experts and healthcare providers to discuss and identify key aspects of early care for children with DMD aged 0-3 years. The meeting emphasized the need for early diagnosis, evidence-based guidelines, and comprehensive care and support for affected children and their families. Further research, collaboration, and the development of consensus guidelines are needed to improve early diagnosis, treatment, and outcomes in this population.
More Related Videos
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
